Last reviewed · How we verify
Daridorexant 50 mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Daridorexant 50 mg (Daridorexant 50 mg) — Legacy Health System.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Daridorexant 50 mg TARGET | Daridorexant 50 mg | Legacy Health System | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Daridorexant 50 mg CI watch — RSS
- Daridorexant 50 mg CI watch — Atom
- Daridorexant 50 mg CI watch — JSON
- Daridorexant 50 mg alone — RSS
Cite this brief
Drug Landscape (2026). Daridorexant 50 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/daridorexant-50-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab